{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:42:11Z","timestamp":1793421731007,"version":"4.5.0"},"reference-count":44,"publisher":"American Chemical Society (ACS)","issue":"22","license":[{"start":{"date-parts":[[2018,11,14]],"date-time":"2018-11-14T00:00:00Z","timestamp":1542153600000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_ccbyncnd_termsofuse.html"}],"funder":[{"DOI":"10.13039\/100001605","name":"Epilepsy Foundation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100001605","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009326","name":"Cancer Research Society","doi-asserted-by":"publisher","award":["CRS-22641"],"award-info":[{"award-number":["CRS-22641"]}],"id":[{"id":"10.13039\/100009326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["310030_153211"],"award-info":[{"award-number":["310030_153211"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["310030B_138659"],"award-info":[{"award-number":["310030B_138659"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["316030_133860"],"award-info":[{"award-number":["316030_133860"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001808","name":"Kommission f\u00fcr Technologie und Innovation","doi-asserted-by":"publisher","award":["PFLS-LS 14032.1"],"award-info":[{"award-number":["PFLS-LS 14032.1"]}],"id":[{"id":"10.13039\/501100001808","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001808","name":"Kommission f\u00fcr Technologie und Innovation","doi-asserted-by":"publisher","award":["PFLS-LS 15811.2"],"award-info":[{"award-number":["PFLS-LS 15811.2"]}],"id":[{"id":"10.13039\/501100001808","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001808","name":"Kommission f\u00fcr Technologie und Innovation","doi-asserted-by":"publisher","award":["PFLS-LS 17241.1"],"award-info":[{"award-number":["PFLS-LS 17241.1"]}],"id":[{"id":"10.13039\/501100001808","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"Stiftung f\u00fcr Krebsbek\u00e4mpfung","doi-asserted-by":"publisher","award":["341"],"award-info":[{"award-number":["341"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mechanistic target of rapamycin (mTOR) promotes cell proliferation, growth, and survival and is overactivated in many tumors and central nervous system disorders. PQR620 (3) is a novel, potent, selective, and brain penetrable inhibitor of mTORC1\/2 kinase. PQR620 (3) showed excellent selectivity for mTOR over PI3K and protein kinases and efficiently prevented cancer cell growth in a 66 cancer cell line panel. In C57BL\/6J and Sprague\u2013Dawley mice, maximum concentration (Cmax) in plasma and brain was reached after 30 min, with a half-life (t1\/2) &amp;gt; 5 h. In an ovarian carcinoma mouse xenograft model (OVCAR-3), daily dosing of PQR620 (3) inhibited tumor growth significantly. Moreover, PQR620 (3) attenuated epileptic seizures in a tuberous sclerosis complex (TSC) mouse model. In conclusion, PQR620 (3) inhibits mTOR kinase potently and selectively, shows antitumor effects in vitro and in vivo, and promises advantages in CNS indications due to its brain\/plasma distribution ratio.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.8b01262","type":"journal-article","created":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T18:40:32Z","timestamp":1540492832000},"page":"10084-10105","source":"Crossref","is-referenced-by-count":83,"title":["Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine\n(PQR620), a Highly Potent and Selective mTORC1\/2 Inhibitor for Cancer\nand Neurological Disorders"],"prefix":"10.1021","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2833-5481","authenticated-orcid":true,"given":"Denise","family":"Rageot","sequence":"first","affiliation":[{"name":"University of Basel , , Mattenstrasse 28 , ,","place":["Basel, Switzerland, 4058"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bohnacker","sequence":"additional","affiliation":[{"name":"University of Basel , , Mattenstrasse 28 , ,","place":["Basel, Switzerland, 4058"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Melone","sequence":"additional","affiliation":[{"name":"University of Basel , , Mattenstrasse 28 , ,","place":["Basel, Switzerland, 4058"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Langlois","sequence":"additional","affiliation":[{"name":"University of Basel , , Mattenstrasse 28 , ,","place":["Basel, Switzerland, 4058"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4688-8362","authenticated-orcid":true,"given":"Chiara","family":"Borsari","sequence":"additional","affiliation":[{"name":"University of Basel , , Mattenstrasse 28 , ,","place":["Basel, Switzerland, 4058"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Hillmann","sequence":"additional","affiliation":[{"name":"PIQUR Therapeutics AG , Hochbergerstrasse 60 , ,","place":["Basel, Switzerland, 4057"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4903-7934","authenticated-orcid":true,"given":"Alexander M.","family":"Sele","sequence":"additional","affiliation":[{"name":"University of Basel , , Mattenstrasse 28 , ,","place":["Basel, Switzerland, 4058"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Beaufils","sequence":"additional","affiliation":[{"name":"University of Basel , , Mattenstrasse 28 , ,","place":["Basel, Switzerland, 4058"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marketa","family":"Zvelebil","sequence":"additional","affiliation":[{"name":"University of Basel , , Mattenstrasse 28 , ,","place":["Basel, Switzerland, 4058"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hebeisen","sequence":"additional","affiliation":[{"name":"PIQUR Therapeutics AG , Hochbergerstrasse 60 , ,","place":["Basel, Switzerland, 4057"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Lo\u0308scher","sequence":"additional","affiliation":[{"name":"University of Veterinary Medicine Hannover, and Center for Systems Neuroscience , , ,","place":["Hannover, Germany, 30559"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7904-9859","authenticated-orcid":true,"given":"John","family":"Burke","sequence":"additional","affiliation":[{"name":"University of Victoria , , , ,","place":["Victoria, British Columbia, Canada, V8W 2Y2"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doriano","family":"Fabbro","sequence":"additional","affiliation":[{"name":"PIQUR Therapeutics AG , Hochbergerstrasse 60 , ,","place":["Basel, Switzerland, 4057"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3349-4281","authenticated-orcid":true,"given":"Matthias P.","family":"Wymann","sequence":"additional","affiliation":[{"name":"University of Basel , , Mattenstrasse 28 , ,","place":["Basel, Switzerland, 4058"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2018,10,25]]},"reference":[{"key":"2026090108490728700_cit1","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nrm2335","article-title":"Lipid signalling\nin disease","volume":"9","author":"Wymann","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2026090108490728700_cit1b","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature12122","article-title":"mTOR kinase\nstructure, mechanism and regulation","volume":"497","author":"Yang","year":"2013","journal-title":"Nature"},{"key":"2026090108490728700_cit1c","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nrm3757","article-title":"Making new contacts: the mTOR network in metabolism\nand signalling crosstalk","volume":"15","author":"Shimobayashi","year":"2014","journal-title":"Nat. Rev. Mol. Cell\nBiol."},{"key":"2026090108490728700_cit1d","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in\ngrowth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"2026090108490728700_cit2","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in\ngrowth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"2026090108490728700_cit3","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1126\/science.1106148","article-title":"Phosphorylation\nand regulation of Akt\/PKB by the rictor-mTOR complex","volume":"307","author":"Sarbassov","year":"2005","journal-title":"Science"},{"key":"2026090108490728700_cit4","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1158\/2159-8290.CD-15-0460","article-title":"PtdIns(3,4,5)P3-dependent activation of the mTORC2\nkinase complex","volume":"5","author":"Liu","year":"2015","journal-title":"Cancer Discovery"},{"key":"2026090108490728700_cit5","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/nrd3531","article-title":"Rapamycin passes\nthe torch: a new generation of mTOR inhibitors","volume":"10","author":"Benjamin","year":"2011","journal-title":"Nat. Rev. Drug Discovery"},{"key":"2026090108490728700_cit6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1126\/science.273.5272.239","article-title":"Structure of the FKBP12-rapamycin\ncomplex interacting with the binding domain of human FRAP","volume":"273","author":"Choi","year":"1996","journal-title":"Science"},{"key":"2026090108490728700_cit7a","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1056\/NEJMoa022171","article-title":"Everolimus for the prevention of allograft rejection\nand vasculopathy in cardiac-transplant recipients","volume":"349","author":"Eisen","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"2026090108490728700_cit7b","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s40267-017-0403-0","article-title":"A review on therapeutic drug monitoring of the mTOR\nclass of immunosuppressants: everolimus and sirolimus","volume":"33","author":"Jacob","year":"2017","journal-title":"Drugs Ther Perspect"},{"key":"2026090108490728700_cit7c","doi-asserted-by":"publisher","first-page":"26","DOI":"10.21767\/2472-5056.100026","article-title":"mTOR Inhibitors in the current practice","volume":"1","author":"Alalawi","year":"2017","journal-title":"J. Clin. Exp. Nephrol."},{"key":"2026090108490728700_cit8","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1161\/01.CIR.0000163587.36485.A7","article-title":"Molecular basis of restenosis and drug-eluting stents","volume":"111","author":"Costa","year":"2005","journal-title":"Circulation"},{"key":"2026090108490728700_cit9","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced\nrenal cell carcinoma: a double-blind, randomised, placebo-controlled\nphase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"2026090108490728700_cit10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/BCTT.S38679","article-title":"Use of mTOR\ninhibitors in the treatment\nof breast cancer: an evaluation of factors that influence patient\noutcomes","volume":"6","author":"Jerusalem","year":"2014","journal-title":"Breast Cancer: Targets Ther."},{"key":"2026090108490728700_cit11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2174\/157488711793980147","article-title":"Recent clinical trials of mTOR-targeted\ncancer therapies","volume":"6","author":"Arachchige Don","year":"2011","journal-title":"Rev. Recent Clin. Trials"},{"key":"2026090108490728700_cit12","doi-asserted-by":"publisher","first-page":"3831","DOI":"10.4161\/cc.8.23.10070","article-title":"Targeting mTOR globally\nin cancer: thinking beyond rapamycin","volume":"8","author":"Shor","year":"2009","journal-title":"Cell Cycle"},{"key":"2026090108490728700_cit13a","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1158\/1535-7163.MCT-14-0711","article-title":"MLN0128,\nan ATP-competitive mTOR\nkinase inhibitor with potent in vitro and in vivo antitumor activity,\nas potential therapy for bone and soft-tissue sarcoma","volume":"14","author":"Slotkin","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"2026090108490728700_cit13b","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature10912","article-title":"The translational landscape of mTOR\nsignalling steers cancer initiation and metastasis","volume":"485","author":"Hsieh","year":"2012","journal-title":"Nature"},{"key":"2026090108490728700_cit14a","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1158\/1535-7163.MCT-14-1052","article-title":"CC-223, a potent and selective inhibitor\nof mTOR kinase: in vitro and in vivo characterization","volume":"14","author":"Mortensen","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"2026090108490728700_cit14b","doi-asserted-by":"publisher","first-page":"58469","DOI":"10.18632\/oncotarget.17753","article-title":"Preclinical\nstudy of CC223 as a potential anti-ovarian cancer agent","volume":"8","author":"Jin","year":"2017","journal-title":"Oncotarget"},{"key":"2026090108490728700_cit15","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.bmcl.2013.01.019","article-title":"Optimization of potent\nand selective dual mTORC1 and mTORC2 inhibitors:\nthe discovery of AZD8055 and AZD2014","volume":"23","author":"Pike","year":"2013","journal-title":"Bioorg.\nMed. Chem. Lett."},{"key":"2026090108490728700_cit16","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMra055323","article-title":"The tuberous sclerosis\ncomplex","volume":"355","author":"Crino","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"2026090108490728700_cit17","doi-asserted-by":"publisher","first-page":"5422","DOI":"10.1523\/JNEUROSCI.0955-08.2008","article-title":"Response\nof a neuronal model of tuberous\nsclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects\non mTORC1 and Akt signaling lead to improved survival and function","volume":"28","author":"Meikle","year":"2008","journal-title":"J. Neurosci."},{"key":"2026090108490728700_cit18","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1212\/WNL.0000000000003400","article-title":"Long-term treatment of epilepsy with\neverolimus in\ntuberous sclerosis","volume":"87","author":"Krueger","year":"2016","journal-title":"Neurology"},{"key":"2026090108490728700_cit19","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1093\/neuonc\/nov152","article-title":"Differentiating\nthe mTOR inhibitors everolimus and\nsirolimus in the treatment of tuberous sclerosis complex","volume":"17","author":"MacKeigan","year":"2015","journal-title":"Neuro Oncol"},{"key":"2026090108490728700_cit20","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","article-title":"Efficacy and safety of sirolimus\nin lymphangioleiomyomatosis","volume":"364","author":"McCormack","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"2026090108490728700_cit21","doi-asserted-by":"publisher","first-page":"15008","DOI":"10.1038\/npjamd.2015.8","article-title":"The mammalian target of rapamycin\nat the crossroad between cognitive aging and Alzheimer\u2019s disease","volume":"1","author":"Talboom","year":"2015","journal-title":"NPJ. Aging Mech. Dis."},{"key":"2026090108490728700_cit22a","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/ng1362","article-title":"Inhibition of mTOR induces autophagy\nand reduces toxicity of polyglutamine expansions in fly and mouse\nmodels of Huntington disease","volume":"36","author":"Ravikumar","year":"2004","journal-title":"Nat. Genet."},{"key":"2026090108490728700_cit22b","doi-asserted-by":"publisher","first-page":"620","DOI":"10.4161\/auto.4898","article-title":"Small molecule enhancers of rapamycin-induced TOR inhibition\npromote autophagy, reduce toxicity in Huntington\u2019s disease\nmodels and enhance killing of mycobacteria by macrophages","volume":"3","author":"Floto","year":"2007","journal-title":"Autophagy"},{"key":"2026090108490728700_cit23","doi-asserted-by":"publisher","first-page":"7524","DOI":"10.1021\/acs.jmedchem.7b00930","article-title":"5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine\n(PQR309), a potent, brain-penetrant, orally bioavailable, pan-class\nI PI3K\/mTOR inhibitor as clinical candidate in oncology","volume":"60","author":"Beaufils","year":"2017","journal-title":"J. Med. Chem."},{"key":"2026090108490728700_cit24","doi-asserted-by":"publisher","first-page":"14683","DOI":"10.1038\/ncomms14683","article-title":"Deconvolution of\nBuparlisib\u2019s\nmechanism of action defines specific PI3K and tubulin inhibitors for\ntherapeutic intervention","volume":"8","author":"Bohnacker","year":"2017","journal-title":"Nat. Commun."},{"key":"2026090108490728700_cit25a","doi-asserted-by":"publisher","first-page":"9325","DOI":"10.1021\/jacs.7b04457","article-title":"CF2H,\na Hydrogen Bond\nDonor","volume":"139","author":"Sessler","year":"2017","journal-title":"J. Am. Chem. Soc."},{"key":"2026090108490728700_cit25b","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1021\/acs.jmedchem.6b01691","article-title":"Difluoromethyl Bioisostere:\nexamining the \u201clipophilic hydrogen bond donor\u201d concept","volume":"60","author":"Zafrani","year":"2017","journal-title":"J. Med. Chem."},{"key":"2026090108490728700_cit26","doi-asserted-by":"publisher","first-page":"7942","DOI":"10.1021\/jm901415x","article-title":"Morpholine derivatives\ngreatly enhance the selectivity of mammalian target of rapamycin (mTOR)\ninhibitors","volume":"52","author":"Zask","year":"2009","journal-title":"J. Med. Chem."},{"key":"2026090108490728700_cit27","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/S1097-2765(05)00089-4","article-title":"Structural\ndeterminants of phosphoinositide\n3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin,\nand staurosporine","volume":"6","author":"Walker","year":"2000","journal-title":"Mol. Cell"},{"key":"2026090108490728700_cit28","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/nbt.1990","article-title":"Comprehensive\nanalysis of kinase inhibitor selectivity","volume":"29","author":"Davis","year":"2011","journal-title":"Nat.\nBiotechnol."},{"key":"2026090108490728700_cit29","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.neuropharm.2018.08.002","article-title":"The novel,\ncatalytic mTORC1\/2 inhibitor PQR620 and the PI3K\/mTORC1\/2 inhibitor\nPQR530 effectively cross the blood-brain barrier and increase seizure\nthreshold in a mouse model of chronic epilepsy","volume":"140","author":"Brandt","year":"2018","journal-title":"Neuropharmacology"},{"key":"2026090108490728700_cit30","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1158\/1541-7786.MCR-08-0366","article-title":"Targeting melanoma\nwith dual phosphoinositide 3-kinase\/mammalian target of rapamycin\ninhibitors","volume":"7","author":"Marone","year":"2009","journal-title":"Mol. Cancer Res."},{"key":"2026090108490728700_cit31","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces\nupstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O\u2019Reilly","year":"2006","journal-title":"Cancer Res."},{"key":"2026090108490728700_cit32","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.molmet.2014.06.004","article-title":"Acute mTOR\ninhibition induces insulin resistance and\nalters substrate utilization in vivo","volume":"3","author":"Kleinert","year":"2014","journal-title":"Mol. Metab."},{"key":"2026090108490728700_cit33","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/ana.21331","article-title":"Rapamycin prevents epilepsy in a\nmouse model of tuberous sclerosis complex","volume":"63","author":"Zeng","year":"2008","journal-title":"Ann.\nNeurol."},{"key":"2026090108490728700_cit34","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1021\/ml200156t","article-title":"Identification\nof NVP-BKM120 as a potent, selective, orally bioavailable class I\nPI3 kinase inhibitor for treating cancer","volume":"2","author":"Burger","year":"2011","journal-title":"ACS\nMed. Chem. Lett."},{"key":"2026090108490728700_cit35","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nbt1068","article-title":"A small molecule-kinase\ninteraction map for clinical kinase inhibitors","volume":"23","author":"Fabian","year":"2005","journal-title":"Nat. Biotechnol."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.8b01262","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/61\/22\/10084\/67439362\/acs.jmedchem.8b01262.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/61\/22\/10084\/67439362\/acs.jmedchem.8b01262.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:49:16Z","timestamp":1788266956000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/61\/22\/10084\/764897\/Discovery-and-Preclinical-Characterization-of-5-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,25]]},"references-count":44,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2018,10,25]]},"published-print":{"date-parts":[[2018,11,21]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.8b01262","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,25]]}}}